215 related articles for article (PubMed ID: 34219488)
41. Comparison of Retinal Layer Thickness in Eyes with Resolved Diabetic Macular Edema Receiving Ranibizumab with Normal Eyes.
Rentiya ZS; Kherani S; Usmani B; Qazi MA; Sadiq MA; Iftikhar M; Nguyen QD; Shah SM; Sepah YJ;
Ophthalmologica; 2020; 243(1):27-36. PubMed ID: 31747663
[TBL] [Abstract][Full Text] [Related]
42. Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?
Ozsaygılı C; Bayram N
Int Ophthalmol; 2024 Feb; 44(1):51. PubMed ID: 38336941
[TBL] [Abstract][Full Text] [Related]
43. Structural and functional assessment after intravitreal injection of ranibizumab in diabetic macular edema.
Fu Y; Wang P; Meng X; Du Z; Wang D
Doc Ophthalmol; 2017 Dec; 135(3):165-173. PubMed ID: 28756595
[TBL] [Abstract][Full Text] [Related]
44. Predictive capacity of baseline hyperreflective dots on the intravitreal dexamethasone implant (Ozurdex®) outcomes in diabetic macular edema: a multicenter study.
Fonollosa A; Zarranz-Ventura J; Valverde A; Becerra E; Bernal-Morales C; Pastor-Idoate S; Zapata MA
Graefes Arch Clin Exp Ophthalmol; 2019 Nov; 257(11):2381-2390. PubMed ID: 31451909
[TBL] [Abstract][Full Text] [Related]
45. Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice.
Sato S; Shinoda H; Nagai N; Suzuki M; Uchida A; Kurihara T; Kamoshita M; Tomita Y; Iyama C; Minami S; Yuki K; Tsubota K; Ozawa Y
Medicine (Baltimore); 2017 Apr; 96(16):e6459. PubMed ID: 28422835
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the efficacy of anti-vascular endothelial growth factors in diabetic macular edema with retinal inner and outer layers disorganization.
Kocapınar Y; Kaplan FB; Demirciler Sönmez A; Açıkalın B
Acta Diabetol; 2023 Oct; 60(10):1391-1398. PubMed ID: 37378699
[TBL] [Abstract][Full Text] [Related]
47. The macular function and structure in patients with diabetic macular edema before and after ranibizumab treatment.
Nowacka B; Kirkiewicz M; Mozolewska-Piotrowska K; Lubiński W
Doc Ophthalmol; 2016 Apr; 132(2):111-22. PubMed ID: 27000269
[TBL] [Abstract][Full Text] [Related]
48. Retinal Layers Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Anti-VEGF Agents: Long-Term Outcomes of a Spectral-Domain OCT Study.
Chatziralli I; Kazantzis D; Theodossiadis G; Theodossiadis P; Sergentanis TN
Ophthalmic Res; 2021; 64(2):230-236. PubMed ID: 32564022
[TBL] [Abstract][Full Text] [Related]
49. Hyperreflective Foci in the Outer Retinal Layers as a Predictor of the Functional Efficacy of Ranibizumab for Diabetic Macular Edema.
Yoshitake T; Murakami T; Suzuma K; Dodo Y; Fujimoto M; Tsujikawa A
Sci Rep; 2020 Jan; 10(1):873. PubMed ID: 31964970
[TBL] [Abstract][Full Text] [Related]
50. Hyperreflective Foci in Diabetic Macular Edema with Subretinal Fluid: Association with Visual Outcomes after Anti-VEGF Treatment.
Tang L; Luo D; Qiu Q; Xu GT; Zhang J
Ophthalmic Res; 2023; 66(1):39-47. PubMed ID: 35697006
[TBL] [Abstract][Full Text] [Related]
51. Real-World Outcomes after 36-Month Treatment with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema (BOREAL-DME).
Massin P; Creuzot-Garcher C; Kodjikian L; Girmens JF; Delcourt C; Fajnkuchen F; Glacet-Bernard A; Guillausseau PJ; Guthux F; Blin P; Grelaud A
Ophthalmic Res; 2021; 64(4):577-586. PubMed ID: 32932257
[TBL] [Abstract][Full Text] [Related]
52. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
[TBL] [Abstract][Full Text] [Related]
53. Association between the patterns of diabetic macular edema and photoreceptors' response after intravitreal ranibizumab treatment: a spectral-domain optical coherence tomography study.
Chatziralli I; Theodossiadis G; Dimitriou E; Kazantzis D; Theodossiadis P
Int Ophthalmol; 2020 Oct; 40(10):2441-2448. PubMed ID: 32424527
[TBL] [Abstract][Full Text] [Related]
54. Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion.
Yiu G; Welch RJ; Wang Y; Wang Z; Wang PW; Haskova Z
Ophthalmol Retina; 2020 Jan; 4(1):67-76. PubMed ID: 31669329
[TBL] [Abstract][Full Text] [Related]
55. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
[TBL] [Abstract][Full Text] [Related]
56. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema.
Nepomuceno AB; Takaki E; Paes de Almeida FP; Peroni R; Cardillo JA; Siqueira RC; Scott IU; Messias A; Jorge R
Am J Ophthalmol; 2013 Sep; 156(3):502-510.e2. PubMed ID: 23795985
[TBL] [Abstract][Full Text] [Related]
57. Choroidal Thickness After Dexamethasone Implant or Aflibercept in Patients with Diabetic Macular Edema Persistent to Ranibizumab.
Aksoy M; Yilmaz G; Vardarli I; Akkoyun I
J Ocul Pharmacol Ther; 2020 Oct; 36(8):629-635. PubMed ID: 32460600
[No Abstract] [Full Text] [Related]
58. Morphological and functional changes in recalcitrant diabetic macular oedema after intravitreal dexamethasone implant.
Iacono P; Parodi MB; Scaramuzzi M; Bandello F
Br J Ophthalmol; 2017 Jun; 101(6):791-795. PubMed ID: 27625164
[TBL] [Abstract][Full Text] [Related]
59. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
Ozkaya A; Tarakcioglu HN; Tanir I
Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
[TBL] [Abstract][Full Text] [Related]
60. Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema.
Minami Y; Nagaoka T; Ishibazawa A; Yoshida A
BMC Ophthalmol; 2017 Mar; 17(1):28. PubMed ID: 28292270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
